title: Is sirolimus responsible for proteinuria?
abstract: Sirolimus (SRL) is suspected to induce proteinuria. We retrospectively studied proteinuria in a population of liver (n = 29) and kidney transplant (n = 30) recipients switched to SRL with progressive diminution or withdrawal of calcineurin inhibitors (CNI). We also observed estimated glomerular filtration rate (GFR), modification of treatment with antiproteinuric drugs, and changes in concentration of SRL. Collection of data started 3 months before SRL introduction at a mean follow-up of 21 months. Following SRL introduction, proteinuria was not detected in the 28 liver transplant patients, and was stable in the two others. In the kidney transplant group, proteinuria did not occur in 12 patients, remained stable in three, and was slightly increased in 14 (0.57 +/- 0.93 g/d vs 1.83 +/- 1.26 g/d). For all patients, eGFR remained stable; there was no difference in management of antiproteinuric drugs. As suspected, cyclosporin (CsA) and tacrolimus (FK) serum concentrations were decreased. We observed a significant correlation between the variation of proteinuria and the variation of serum concentration of CsA or FK (respectively, P = .001 and P = .007). On the other hand, we did not find any correlation between variation in proteinuria and concentration of SRL. This retrospective study suggests that in our cohort of liver transplant patients without previous renal damage, SRL did not provoke proteinuria. On the other hand, the slight aggravation of proteinuria in a subgroup of kidney transplant patients seems to be linked to the hemodynamic renal effects due to CNI withdrawal.
authors.affiliation: Service de Néphrologie et Transplantation, CHU Strasbourg, France. thomas.dervaux@chru-strasbourg.fr
authors.forename: T
authors.initials: T
authors.lastname: Dervaux
authors.forename: S
authors.initials: S
authors.lastname: Caillard
authors.forename: C
authors.initials: C
authors.lastname: Meyer
authors.forename: B
authors.initials: B
authors.lastname: Ellero
authors.forename: M L
authors.initials: ML
authors.lastname: Woehl-Jaegle
authors.forename: T
authors.initials: T
authors.lastname: Hannedouche
authors.forename: P
authors.initials: P
authors.lastname: Wolf
authors.forename: B
authors.initials: B
authors.lastname: Moulin
mesh_terms: D005576:Colforsin / Q000097:blood / Q000627:therapeutic use; D016572:Cyclosporine / Q000097:blood / Q000627:therapeutic use; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects; D016030:Kidney Transplantation / Q000276:immunology*; D016031:Liver Transplantation / Q000276:immunology*; D011507:Proteinuria / Q000139:chemically induced*; D012189:Retrospective Studies; D020123:Sirolimus / Q000009:adverse effects*
chemical_list: D007166:Immunosuppressive Agents; D005576:Colforsin; D016572:Cyclosporine; D020123:Sirolimus